ADVM vs. URGN

Last updated Apr 2, 2026

Compare and contrast key facts about Adverum Biotechnologies, Inc. (ADVM) and UroGen Pharma Ltd. (URGN).

Performance

ADVM vs. URGN - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Adverum Biotechnologies, Inc. (ADVM) and UroGen Pharma Ltd. (URGN). The values are adjusted to include any dividend payments, if applicable.

ADVM vs. URGN - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018	2017
ADVM Adverum Biotechnologies, Inc.	0.00%	-6.64%	-37.96%	29.91%	-67.07%	-83.76%	-5.90%	265.71%	-10.00%	22.81%
URGN UroGen Pharma Ltd.	-19.13%	119.91%	-29.00%	69.11%	-6.73%	-47.23%	-46.00%	-22.50%	15.72%	166.17%

Fundamentals

Market Cap ADVM : $102.40M URGN : $932.42M
EPS ADVM : -$9.19 URGN : -$3.18
Total Revenue (TTM) ADVM : $0.00 URGN : $109.79M
Gross Profit (TTM) ADVM : -$465.00K URGN : $97.34M
EBITDA (TTM) ADVM : -$205.45M URGN : -$127.69M

Returns By Period

ADVM

• 1D: 0.00%
• 1M: 0.00%
• YTD: 0.00%
• 6M: -12.97%
• 1Y: 13.84%
• 3Y*: -15.30%
• 5Y*: -46.64%
• 10Y*: -21.95%

URGN

• 1D: 5.34%
• 1M: -0.42%
• YTD: -19.13%
• 6M: 6.31%
• 1Y: 78.17%
• 3Y*: 27.03%
• 5Y*: -0.71%
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

ADVM vs. URGN — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

ADVM

ADVM Risk / Return Rank: 46
ADVM Sharpe Ratio Rank: 47
ADVM Sortino Ratio Rank: 53
ADVM Omega Ratio Rank: 52
ADVM Calmar Ratio Rank: 39
ADVM Martin Ratio Rank: 40

URGN

URGN Risk / Return Rank: 69
URGN Sharpe Ratio Rank: 65
URGN Sortino Ratio Rank: 73
URGN Omega Ratio Rank: 76
URGN Calmar Ratio Rank: 64
URGN Martin Ratio Rank: 66

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

ADVM vs. URGN - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Adverum Biotechnologies, Inc. (ADVM) and UroGen Pharma Ltd. (URGN). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	ADVM	URGN	Difference
Sharpe ratio Return per unit of total volatility	0.20	0.69	-0.49
Sortino ratio Return per unit of downside risk	0.96	1.78	-0.81
Omega ratio Gain probability vs. loss probability	1.12	1.27	-0.14
Calmar ratio Return relative to maximum drawdown	-0.02	1.08	-1.09
Martin ratio Return relative to average drawdown	-0.03	3.00	-3.03
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

ADVM vs. URGN - Sharpe Ratio Comparison

The current ADVM Sharpe Ratio is 0.20, which is lower than the URGN Sharpe Ratio of 0.69. The chart below compares the historical Sharpe Ratios of ADVM and URGN, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	ADVM	URGN	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	0.20	0.69	-0.49
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	-0.58	-0.01	-0.57
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	-0.27	—	—
Sharpe Ratio (All Time) Calculated using the full available price history	-0.32	0.04	-0.36

Correlation

The correlation between ADVM and URGN is 0.25, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Dividends

ADVM vs. URGN - Dividend Comparison

Neither ADVM nor URGN has paid dividends to shareholders.

Tickers have no history of dividend payments

Drawdowns

ADVM vs. URGN - Drawdown Comparison

The maximum ADVM drawdown since its inception was -99.20%, which is greater than URGN's maximum drawdown of -93.98%. Use the drawdown chart below to compare losses from any high point for ADVM and URGN.

Drawdown Indicators

	ADVM	URGN	Difference
Max Drawdown Largest peak-to-trough decline	-99.20%	-93.98%	-5.22%
Max Drawdown (1Y) Largest decline over 1 year	-51.88%	-66.24%	+14.36%
Max Drawdown (5Y) Largest decline over 5 years	-98.06%	-82.64%	-15.42%
Max Drawdown (10Y) Largest decline over 10 years	-99.20%	—	—
Current Drawdown Current decline from peak	-98.30%	-71.01%	-27.29%
Average Drawdown Average peak-to-trough decline	-69.23%	-61.55%	-7.68%
Ulcer Index Depth and duration of drawdowns from previous peaks	37.59%	23.79%	+13.80%

Volatility

ADVM vs. URGN - Volatility Comparison

The current volatility for Adverum Biotechnologies, Inc. (ADVM) is 0.00%, while UroGen Pharma Ltd. (URGN) has a volatility of 15.35%. This indicates that ADVM experiences smaller price fluctuations and is considered to be less risky than URGN based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	ADVM	URGN	Difference
Volatility (1M) Calculated over the trailing 1-month period	0.00%	15.35%	-15.35%
Volatility (6M) Calculated over the trailing 6-month period	49.41%	49.37%	+0.04%
Volatility (1Y) Calculated over the trailing 1-year period	84.03%	113.74%	-29.71%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	82.34%	91.48%	-9.14%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	81.87%	79.73%	+2.14%

Financials